Open AccessMelatonin Treatment Enhances Aβ Lymphatic Clearance in a Transgenic Mouse Model of Amyloidosis
Author(s) -
Miguel A. Pappolla,
Etsuro Matsubara,
Rubén Vidal,
Javier PachecoQuinto,
Burkhard Pöeggeler,
Michael G. Zagorski,
Kumar Sambamurti
Publication year - 2018
Publication title -
current alzheimer research
Language(s) - English
Resource type - Journals
eISSN - 1875-5828
pISSN - 1567-2050
DOI - 10.2174/1567205015666180411092551
Subject(s) - lymphatic system , clearance , lymph , genetically modified mouse , pathology , transgene , amyloidosis , lymphatic vessel , medicine , biology , cancer , metastasis , urology , biochemistry , gene
It has been postulated that inadequate clearance of the amyloid β protein (Aβ) plays an important role in the accumulation of Aβ in sporadic late onset Alzheimer's disease (AD). While the blood brain barrier (BBB) has taken the center stage in processes involving Aβ clearance, little information is available about the role of the lymphatic system. We previously reported that Aβ is cleared through the lymphatic system. We now assessed lymphatic Aβ clearance by treating a mouse model of AD amyloidosis with melatonin, an Aβ aggregation inhibitor and immuno-regulatory neurohormone.